ArticleThrombosis journal2024

Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2/3 study in Japan.

Kazunori Imada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.